$0.75
6.19% yesterday
Nasdaq, May 20, 10:16 pm CET
ISIN
US0044461004
Symbol
ACET
Sector
Industry

Adicet Bio Inc Stock price

$0.75
+0.18 31.84% 1M
-0.22 22.51% 6M
-0.21 22.10% YTD
-0.87 53.74% 1Y
-9.86 92.94% 3Y
-12.97 94.54% 5Y
-117.41 99.37% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.04 6.19%
ISIN
US0044461004
Symbol
ACET
Sector
Industry

Key metrics

Market capitalization $61.98m
Enterprise Value $-72.21m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.74
P/B ratio (TTM) P/B ratio 0.38
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-126.63m
Free Cash Flow (TTM) Free Cash Flow $-97.30m
Cash position $150.44m
EPS (TTM) EPS $-1.29
P/E forward negative
Short interest 3.30%
Show more

Is Adicet Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Adicet Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Adicet Bio Inc forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Adicet Bio Inc forecast:

Buy
71%
Hold
29%

Financial data from Adicet Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 6.50 6.50
18% 18%
-
-6.50 -6.50
18% 18%
-
- Selling and Administrative Expenses 15 15
40% 40%
-
- Research and Development Expense 98 98
5% 5%
-
-120 -120
2% 2%
-
- Depreciation and Amortization 6.50 6.50
18% 18%
-
EBIT (Operating Income) EBIT -127 -127
3% 3%
-
Net Profit -117 -117
16% 16%
-

In millions USD.

Don't miss a Thing! We will send you all news about Adicet Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adicet Bio Inc Stock News

Neutral
Business Wire
14 days ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2025. “We are approaching an exciting inflection point for our pipeline, wit...
Neutral
Business Wire
20 days ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on April 30, 2025. Three individuals were hired by Adicet in April 2025. In the aggregate, Adicet granted new hires non-qualified...
Neutral
Business Wire
21 days ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from ...
More Adicet Bio Inc News

Company Profile

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.

Head office United States
CEO Chen Schor
Employees 152
Founded 2014
Website www.adicetbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today